Please use this identifier to cite or link to this item:
|Title:||Evaluation of a prednisolone acetate-loaded subconjunctival implant for the treatment of recurrent uveitis in a rabbit model||Authors:||Ang M.
in vitro study
in vivo study
randomized controlled trial
analogs and derivatives
drug administration route
prostheses and orthoses
Drug Administration Routes
Prostheses and Implants
|Issue Date:||2014||Citation:||Ang M., Ng X., Wong C., Yan P., Chee S.-P., Venkatraman S.S., Wong T.T. (2014). Evaluation of a prednisolone acetate-loaded subconjunctival implant for the treatment of recurrent uveitis in a rabbit model. PLoS ONE 9 (5) : e97555. ScholarBank@NUS Repository. https://doi.org/10.1371/journal.pone.0097555||Abstract:||Aim: To assess the efficacy of a biodegradable, prednisolone acetate implant in a rabbit uveitis model. Methods: Randomized, controlled study of biodegradable microfilms preloaded with prednisolone acetate (PA) in a rabbit uveitis model. Experimental uveitis was induced by unilateral intravitreal injection of Mycobacterium tuberculosis H37Ra antigen (50 ug; 1 ug/uL) in preimmunized rabbits. PA-loaded poly[d,l-lactide-co-?-caprolactone] (PLC) microfilms (n = 10) and blank microfilms (n = 6) were implanted subconjunctivally. An estimate of PA release in vivo was calculated from measured residual PA amounts in microfilms after the rabbits were sacrificed. The eyes were clinically monitored for ocular inflammation for 28 days. Histopathological examination of the enucleated eyes was performed at the end of the study period. Results: In vitro studies revealed that sandwich PA-loaded microfilm formulations exhibited higher release kinetic compared to homogenous PA-loaded microfilms. The 60-40-60% microfilm released an average of 0.034 mg/day of PA over the period of 60 days in vitro; and we found that approximately 0.12 mg/day PA was released in vivo. Animals implanted with the PA-loaded microfilms exhibited significantly lowered median inflammatory scores when compared against the control group in this model for recurrent uveitis (P<0.001). The implants were clinically well tolerated by all the animals. Histology results showed no significant scarring or inflammation around the PA-loaded microfilms. Conclusion: Our pilot study demonstrated that a subconjunctival PA-loaded implant is effective in suppressing inflammation in the rabbit model of uveitis, by providing therapeutic levels of PA that attenuated the inflammatory response even after a rechallenge. Longer term studies are now needed to establish the therapeutic potential of such a delivery system for treatment of ocular inflammation. © 2014 Ang et al.||Source Title:||PLoS ONE||URI:||https://scholarbank.nus.edu.sg/handle/10635/161411||ISSN:||1932-6203||DOI:||10.1371/journal.pone.0097555|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
|10_1371_journal_pone_0097555.pdf||1.13 MB||Adobe PDF|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.